



*ASX Limited
Market Announcements Office*

Settlement Negotiations

13 December 2018, Melbourne: Australian drug delivery company, Phosphagenics Limited (ASX: POH, OTCQX: PPGNY), advises that it is continuing with advanced negotiations with Mylan in relation to the quantum of costs that might be payable under the arbitration and future arrangements for commercialisation of the intellectual property that has been under dispute.

Accordingly the Company will remain in trading suspension until it announces finalisation of the agreements which are expected to be concluded by 14 December 2018.

Enquiries

Ms Anna Legg
Chief Financial Officer
Phosphagenics Limited
+61 3 9002 5000

About Phosphagenics

Phosphagenics Limited is focused on developing and commercialising innovative Human Health, Animal Health and Personal Care products using its proprietary drug delivery system called TPM[®] (Tocopheryl Phosphate Mixture). TPM[®] is derived from Vitamin E using a unique, proprietary and patented process and has been proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Amongst its major projects, Phosphagenics' is developing TPM[®] enhanced patches, gels and injectable products for the human health market and is also developing TPM[®] to enhance the feed efficiency and health of livestock.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

www.phosphagenics.com